available for iOS, Android & web
August 02, 2012
Halozyme Therapeutics saw its stock collapse 53.7% in after-hours trading as regulators in the USA turned down an immune deficiency product from Baxter that uses technology developed by the former
April 17, 2012
Shares in Halozyme Therapeutics have plummeted further this week on the back of news that US regulators are seeking more information on the company’s immune system boosting drug.
Making patients smile
Patients’ wellbeing can be just as important as
International Clinical Researcher of the Year 2016
Book your tickets today!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions